SCHEMBL4396146

SCHEMBL4396146

O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccccn4)c3c2)S1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 7/20 0.69
PIK3CA P42336 4/20 0.69
PIK3CG P48736 4/20 0.69
PIK3CD O00329 3/20 0.69
CSNK2A2 P19784 3/20 0.69
CLK1 P49759 3/20 0.69
DYRK1A Q13627 3/20 0.69
PIK3CB P42338 2/20 0.69
MTOR P42345 2/20 0.69
GAK O14976 1/20 0.69
RPS6KA4 O75676 1/20 0.69
STK10 O94804 1/20 0.69
MAP2K2 P36507 1/20 0.69
CSNK1D P48730 1/20 0.69
CLK2 P49760 1/20 0.69
CSNK1G2 P78368 1/20 0.69
MAP2K1 Q02750 1/20 0.69
AAK1 Q2M2I8 1/20 0.69
Q6ZSR9 Q6ZSR9 1/20 0.69
TAOK1 Q7L7X3 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4396147 1.00 PIM1 (0.69) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
SCHEMBL4393990 0.88 PIM1 (0.68) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
SCHEMBL4393984 0.88 PIM1 (0.68) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
Gsk-1059615 SCHEMBL1805560 0.82 PIK3CA (1.00) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
Gsk-1059615 SCHEMBL29381321 0.82 PIK3CA (1.00) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
Gsk-1059615 SCHEMBL1805561 0.82 PIK3CA (1.00) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
Gsk-1059615 SCHEMBL29351551 0.82 PIK3CA (1.00) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
Gsk-1059615 SCHEMBL1805557 0.82 PIK3CA (1.00) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
SCHEMBL4203735 0.81 PIM1 (0.71) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2
SCHEMBL4201522 0.81 PIM1 (0.71) PIM1PIK3CAPIK3CGPIK3CDCSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306074-A1 THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-12-10 US claimed
EP-2004189-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 EP claimed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US claimed
WO-2007136940-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO claimed
US-20090306074-A1 THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-12-10 US disclosed
US-20090306074-A1 THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-12-10 US disclosed
US-20090306074-A1 THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-12-10 US disclosed
EP-2004189-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-24 EP disclosed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US disclosed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US disclosed
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS DARCY MICHAEL GERARD 2008-10-16 US disclosed
WO-2007136940-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO disclosed
WO-2007136940-A2 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255115-A1 THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS PI4KA, JAK3, PIK3CD PIM1 280/4885PIK3CA 14/4885PIK3CG 10/4885
US-20090306074-A1 THIAZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS JAK3, DPP3, ADRB3 PIM1 717/4885PIK3CA 43/4885PIK3CG 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.